Brief: Eyconis Announces Initiation Of First-In-Human Clinical Trial Of Eyc-0305 In Treatment-Naïve Wet Age-Related Macular Degeneration Patients
18/08/2026 13:11
BRIEF-Eyconis Announces Initiation Of First-In-Human Clinical Trial Of Eyc-0305 In Treatment-Naïve Wet Age-Related Macular Degeneration Patients Ascendis Pharma A/S ASND.O:
EYCONIS ANNOUNCES INITIATION OF FIRST-IN-HUMAN CLINICAL TRIAL OF EYC-0305 IN TREATMENT-NAÏVE WET AGE-RELATED MACULAR DEGENERATION PATIENTS
Source text: ID:nGNXc52pRS
Further company coverage: ASND.O
Recent news on Ascendis Pharma A/S
See all newsAscendis Pharma tumbles on Novo Nordisk collab termination
BioMarin climbs on global patent settlement with Ascendis
Brief: Ascendis Announces Oral Presentation Of Week 104 Data From Its Pivotal Trial Of Transcon® CNP (Navepegritide) At Isds 2026
Brief: Eyconis Announces Initiation Of First-In-Human Clinical Trial Of Eyc-0305 In Treatment-Naïve Wet Age-Related Macular Degeneration Patients
Ascendis Pharma A/S reports results for the quarter ended June 30 - Earnings Summary